DexCom price target raised to $104 from $101 at Citi

Citi raised the firm’s price target on DexCom (DXCM) to $104 from $101 and keeps a Buy rating on the shares. The firm adjusted medical technology models post the Q4 reports. The prints “were largely benign compared to a chaotic” Q2 and Q3, the analyst tells investors in a research note.